Heart rate variability(HRV)analysis provides an assessment of cardiac vagal tone and consequently global cardiac health as well as systemic condition.In systemic diseases such as cancer and during treatments that affe...Heart rate variability(HRV)analysis provides an assessment of cardiac vagal tone and consequently global cardiac health as well as systemic condition.In systemic diseases such as cancer and during treatments that affect the whole body,like chemotherapy,the vagus nerve activity is low and deregulated.Some studies focus on using HRV to predict mortality in oncology.However,in cancer patients,systemic alterations substantially increase artifacts during HRV measurement,especially atrial ectopic beats.Moreover,HRV may be altered by various factors(duration and time of measurement,breathing,drugs,and other confounding factors)that alter each metric in different ways.The Standard Deviation of all Normal to Normal intervals(SDNN)is the most commonly used metric to evaluate HRV in oncology,but it does not appear to be specific to the cardiac vagal tone.Thus,cardiac vagal activity diagnosis and vital prognosis of cancer patients can be biased.Our review presents the main HRV metrics that can be currently used in oncology studies and their links with vagus nerve and cancer.We present the influence of external factors and the required duration and time of measurement.Considering all these parameters,this review proposes seven key points for an assessment of HRV and cardiac vagal tone in patients with cancer.展开更多
Elevated heart rate is a major risk factor for cardiovascular diseases. The inhibitor of funny current （I （f） ）, a hyperpolarization-activated cyclic nucleotide-gated channel current, ivabradine is a new agent sel...Elevated heart rate is a major risk factor for cardiovascular diseases. The inhibitor of funny current （I （f） ）, a hyperpolarization-activated cyclic nucleotide-gated channel current, ivabradine is a new agent selectively reducing heart rate devoid of other cardiovascular effects, which has come into the market in Europe for more than 3 years. It has been approved that pure heart rate reduction by ivabradine can improve myocardial ischernia, endothelial function and myocardial contractile function. Long-term administration will not increase all-cause mortality. Its therapeutic value in stable coronary artery disease has been verified in clinical practice, while in other fields of cardiovascular diseases still needs more evidence-based medical research. This article is a review about its recent research advances in experimental and clinical studies.展开更多
文摘Heart rate variability(HRV)analysis provides an assessment of cardiac vagal tone and consequently global cardiac health as well as systemic condition.In systemic diseases such as cancer and during treatments that affect the whole body,like chemotherapy,the vagus nerve activity is low and deregulated.Some studies focus on using HRV to predict mortality in oncology.However,in cancer patients,systemic alterations substantially increase artifacts during HRV measurement,especially atrial ectopic beats.Moreover,HRV may be altered by various factors(duration and time of measurement,breathing,drugs,and other confounding factors)that alter each metric in different ways.The Standard Deviation of all Normal to Normal intervals(SDNN)is the most commonly used metric to evaluate HRV in oncology,but it does not appear to be specific to the cardiac vagal tone.Thus,cardiac vagal activity diagnosis and vital prognosis of cancer patients can be biased.Our review presents the main HRV metrics that can be currently used in oncology studies and their links with vagus nerve and cancer.We present the influence of external factors and the required duration and time of measurement.Considering all these parameters,this review proposes seven key points for an assessment of HRV and cardiac vagal tone in patients with cancer.
文摘Elevated heart rate is a major risk factor for cardiovascular diseases. The inhibitor of funny current （I （f） ）, a hyperpolarization-activated cyclic nucleotide-gated channel current, ivabradine is a new agent selectively reducing heart rate devoid of other cardiovascular effects, which has come into the market in Europe for more than 3 years. It has been approved that pure heart rate reduction by ivabradine can improve myocardial ischernia, endothelial function and myocardial contractile function. Long-term administration will not increase all-cause mortality. Its therapeutic value in stable coronary artery disease has been verified in clinical practice, while in other fields of cardiovascular diseases still needs more evidence-based medical research. This article is a review about its recent research advances in experimental and clinical studies.
